2012 Midyear Clinical Meeting
Click here to go to the previous page
A 'Bloody' Debate - Which Agent is Best to Prevent Stroke in a Treatment Naive Atrial Fibrillation Patient?
Track:
Education Sessions (CE)
Program Code: 250-L01
Date: Monday, December 3, 2012
Time: 2:00 PM to 4:00 PM EST
Location:
Mandalay Bay H, Level 2, South Convention Center
PRESENTER(S):
Click the plus sign to see more detailed information about each speaker.
Nathan Clark,
PharmD, BCPS, Clinical Pharmacy Supervisor,
Kaiser Permanente Colorado
|
Dr. Clark completed his Pharm D at North Dakota State University in 2002 and pharmacy practice residency at Merit Care Health System in 2003. Since joining the clinical pharmacy team at Kaiser Permanente Colorado in 2003, his major focus has been ambulatory anticoagulation management and research. Peer-reviewed publications and scholarly activities have focused on excessive anticoagulation, anticoagulation in pregnancy, perioperative anticoagulation management, and warfarin management after bleeding complications. Dr. Clark became a supervisor of the Clinical Pharmacy Anticoagulation and Anemia Service at Kaiser Permanente Colorado in 2009. This team of 20 clinical pharmacists and 3 pharmacy technicians provides comprehensive anticoagulation care to greater than 8,000 Kaiser Permanente members in Colorado.
Dr. Clark is also a clinical instructor with the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences.
|
William Dager,
PharmD, BCPS, Pharmacist Specialist,
University of California Davis Medical Center
|
William E. Dager, Pharm.D, BCPS (AQ Cardiology)
FCSHP, FCCP, FCCM, FASHP
Pharmacist Specialist, UC Davis Medical Center (UCDMC)
Clinical Professor of Pharmacy
University of California, San Francisco
Clinical Professor of Medicine
School of University of California, Davis
Clinical Professor of Pharmacy, Touro School of Pharmacy
William E. Dager, received his Pharm.D. from the University of California, San Francisco (UCSF) and completed a residency at UCDMC. He also completed a Nephrology Pharmaceutical Care Preceptorship at the University of Pittsburgh, School of Pharmacy. He is a board certified pharmacotherapy specialist with added qualifications in cardiology, who is a clinical specialist at UCDMC where he manages difficult cases in anticoagulation, pharmacokinetics or other critical care related situations. He is the director of the PGY-2 residency in cardiology. He currently holds four academic positions primarily as volunteer faculty.
Dr Dager is a recipient of multiple teaching and mentoring awards including the ACCP Best Practice award. He is a reviewer and/or editorial board member for multiple medical journals including chair of the Editorial Advisory Board panel on anticoagulation for the Annals of Pharmacotherapy. He is also a site coordinator for the ASHP foundation anticoagulation preceptorship.
Dr Dager has authored numerous articles, reviews book chapters in including the ASHP Anticoagulation Therapy POC guide. He is an active lecturer and has research interests involving anticoagulation, critical care, cardiovascular disease and pharmacokinetics/pharmacodynamics.
|
Michael Gulseth,
PharmD, BCPS, Program Director for Anticoagulation Services,
Sanford USD Medical Center
|
Michael P. Gulseth, Pharm.D., BCPS, FASHP is the Program Director for Anticoagulation Services as Sanford USD Medical Center in Sioux Falls, SD. He is also an adjunct assistant professor at the South Dakota State University College of Pharmacy. Dr. Gulseth received his Doctor of Pharmacy degree in 1999 from North Dakota State University in Fargo, North Dakota. He completed residency training at United Hospital in St. Paul, Minnesota.
Dr. Gulseth is lead author and editor of Managing Anticoagulation Patients in the Hospital: the Inpatient Anticoagulation Service, published in 2007 by the American Society of Health-System Pharmacists (ASHP). He is a co-editor and author of Anticoagulation Therapy: A Point of Care Guide, published in 2011 by the ASHP.
Dr. Gulseth is an active member of several professional pharmacy organizations, including the ASHP, the Minnesota Society of Health-System Pharmacists (MSHP), the South Dakota Society of Health-System Pharmacists, and the American College of Clinical Pharmacy. He has served on the Editorial Advisory Board of the American Journal of Health-System Pharmacy and is a past president of MSHP. He was elected a Fellow of the ASHP in 2011. His research interests include evaluation of antithrombotic therapies in the inpatient setting and evaluation of the benefits of pharmacist-managed anticoagulation services.
|
Edith Nutescu,
PharmD, FCCP, Clinical Professor,
University of Illinois at Chicago, College of Pharmacy
|
Edith A. Nutescu, Pharm.D., FCCP, is Clinical Professor in the Department of Pharmacy Practice, Pharmacy Administration, and Center for Pharmacoeconomic Research at University of Illinois at Chicago College of Pharmacy. Dr. Nutescu maintains an active clinical practice and research program. Her research and practice interests are in the areas of comparative effectiveness, health services and outcomes, with emphasis in cardiovascular diseases, stroke, thrombosis, and antithrombotic therapies. Dr Nutescu has authored over 100 scientific articles and book chapters, and has served as a reviewer for the literature in her field. Dr. Nutescus research has been funded by the Department of Health and Human Services and the National Center for Research Resources and is a recipient of the Ruth L. Kirchstein National Research Service Award for 2009-2012. She serves on the Editorial Boards for Pharmacotherapy, Annals of Pharmacotherapy and Thrombosis, and has served on the editorial board for the American Journal of Health-System Pharmacy. Dr. Nutescu is active in several professional organizations including currently serving on the Board of Regents for the American College of Clinical Pharmacy. Dr. Nutescu has been recognized as a Fellow of the American College of Clinical Pharmacy and is the recipient of the American College of Clinical Pharmacys 2009 Clinical Practice Award and the American Society of Health System Pharmacists, Section of Home and Ambulatory Care Practitioners 2010 Distinguished Service Award.
|
PROGRAM CHAIR:
Click the plus sign to see more detailed information about each speaker.
Michael Gulseth,
PharmD, BCPS, Program Director for Anticoagulation Services,
Sanford USD Medical Center
|
Michael P. Gulseth, Pharm.D., BCPS, FASHP is the Program Director for Anticoagulation Services as Sanford USD Medical Center in Sioux Falls, SD. He is also an adjunct assistant professor at the South Dakota State University College of Pharmacy. Dr. Gulseth received his Doctor of Pharmacy degree in 1999 from North Dakota State University in Fargo, North Dakota. He completed residency training at United Hospital in St. Paul, Minnesota.
Dr. Gulseth is lead author and editor of Managing Anticoagulation Patients in the Hospital: the Inpatient Anticoagulation Service, published in 2007 by the American Society of Health-System Pharmacists (ASHP). He is a co-editor and author of Anticoagulation Therapy: A Point of Care Guide, published in 2011 by the ASHP.
Dr. Gulseth is an active member of several professional pharmacy organizations, including the ASHP, the Minnesota Society of Health-System Pharmacists (MSHP), the South Dakota Society of Health-System Pharmacists, and the American College of Clinical Pharmacy. He has served on the Editorial Advisory Board of the American Journal of Health-System Pharmacy and is a past president of MSHP. He was elected a Fellow of the ASHP in 2011. His research interests include evaluation of antithrombotic therapies in the inpatient setting and evaluation of the benefits of pharmacist-managed anticoagulation services.
|
Description
Debate #1: Dabigatran Etexilate is the Preferred Agent to Prevent Stroke Due to Atrial Fibrillation in a Treatment Naive Patient, Michael P. Gulseth, PharmD, BCPS, FASHP
Debate #2: Rivaroxaban is the Preferred Agent to Prevent Stroke Due to Atrial Fibrillation in a Treatment Naive Patient, Nathan Clark, PharmD, BCPS
Debate #3: Apixaban is the Preferred Agent to Prevent Stroke Due to Atrial Fibrillation in a Treatment Naive Patient, Edith A. Nutescu, PharmD, FCCP
Debate #4: Warfarin is the Preferred Agent to Prevent Stroke Due to Atrial Fibrillation in a Treatment Naive Patient, William E. Dager, PharmD, BCPS, FASHP
Debate Rebuttals, Michael P. Gulseth, PharmD, BCPS, FASHP; Nathan Clark, PharmD, BCPS; Edith A. Nutescu, PharmD, FCCP; William E. Dager, PharmD, BCPS, FASHP
Case Discussions (Focus on Special Patient Populations), William E. Dager, PharmD, BCPS, FASHP; Michael P. Gulseth, PharmD, BCPS, FASHP; Edith A. Nutescu, PharmD, FCCP; Nathan Clark, PharmD, BCPS
- Evaluate and pick an appropriate therapy for a patient who has new atrial fibrillation and needs a medication for stroke prophylaxis.
- Interpret the scientific literature supporting the approval of the agents used to prevent stroke in atrial fibrillation by identifying the strengths and weaknesses of each study.
- Recommend what agent may be preferred in special patient populations (examples: renal dysfunction, interacting medications, etc.)for stroke prophylaxis in atrial fibrillation.
